Vasculitis & polymyalgia rheumatica

Beyond pregnancy in systemic autoimmune diseases: a focus on postpartum experience from a referral centre

Rheumatology (Oxford)Published Retrospective cohort study

Authors' conclusion

The postpartum period is high-risk in SAD patients.

Study context

Population
Pregnancies in patients with systemic autoimmune diseases (SAD) at a referral centre: Connective tissue diseases (CTDs) 80.2%, inflammatory arthritis 14.2%, vasculitis 5.5%
Participants
253 pregnancies
Outcome
Incidence and types of complications (disease flares and other clinical events) postpartum
Follow-up
Within 60 days postpartum
Methodological detailsprospectively collected data, single-centre
  • Prospectively collected data
  • Single-centre

Main finding

As reported in the abstract

Postpartum complications

Any postpartum complication

50

19.8%

Flares

42

16.6%

Other complications

12

4.7%

Observational data: associations, not effects.

Further findings

Flare rate by diagnosis

P < 0.01

Flare rate by diagnosis

Severe flares occurred only in CTD or vasculitis

Flares associated with active disease during pregnancy

Flares associated with active disease during pregnancy
P < 0.01

Non-flare complications by diagnosis

Did not differ by diagnosis

Breastfeeding at postpartum visit

Breastfeeding
147 (58.5%)
Contraindicated to breastfeed due to therapies, among 42 with flares
4

Postpartum visit performed

Postpartum visit performed
234 (92.5%)

Safety

Other (non-flare) postpartum complications · within 60 days postpartum

Hypertension
6
Postpartum hemorrhages (two on LDA/LMWH)
4
Clostridium difficile infection
1
ICU admission for HELLP syndrome
1

Original publication

Beyond pregnancy in systemic autoimmune diseases: a focus on postpartum experience from a referral centre. Rheumatology (Oxford). Published 10 July 2025. doi:10.1093/rheumatology/keaf371

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.